Patients affected by severe genetic and orphan diseases Patients affected by severe genetic and orphan diseases Patients affected by severe genetic and orphan diseases

Transforming the
Lives of Patients

WITH SEVERE GENETIC AND ORPHAN DISEASES

We are developing next generation products based on the transformative potential of gene therapy to treat patients with severe genetic and orphan diseases. We have two clinical stage products in development for childhood cerebral adrenoleukodystrophy and beta-thalassemia/sickle cell disease, a preclinical oncology program in partnership with Celgene, a world-class team and a broadly applicable gene therapy platform READ MORE >>

spotlight

November 12, 2014

bluebird bio Reports Fiscal Third Quarter 2014 Financial Results

Read More

November 10, 2014

James M. DeTore joins bluebird bio as Chief Financial Officer

Read More

November 7, 2014

bluebird bio to Present at Three Upcoming Health Care Conferences

Read More

November 6, 2014

bluebird bio to Present LentiGlobin Clinical Data at the American Society of Hematology Conference

Read More